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Letters to the Editor
First Isolation of blaVIM-2 in Latin America: Report from the SENTRY
Antimicrobial Surveillance Program
Carbapenems, mainly imipenem and meropenem, are po-
tent agents for the treatment of infections due to multiresistant
Pseudomonas sp. clinical isolates. However, the prevalence of
carbapenem resistance in this genus has been increasing world-
wide. High-level resistance to carbapenems (32 g/ml) is still
uncommon in Pseudomonas spp. but can be due to the pres-
ence of Ambler class B -lactamases—metallo--lactamases
(MBLs) (1). Three different clinically relevant types of mobile
MBLs have been described in the literature: IMP, VIM, and
SPM (2, 4; H. Kurokawa, T. Yagi, N. Shibata, K. Shibayama,
and Y. Arakawa, Letter, Lancet 354:955, 1999). The VIM
family has been reported mostly in European and Asian coun-
tries, although a distantly related MBL, VIM-7, has been char-
acterized from the United States (5). We are not aware of
VIM-type MBLs being reported from Latin America. In this
work, we describe the presence of blaVIM-2-producing Pseudo-
monas sp. isolates and characterize their genetic context
among isolates obtained from Latin American medical centers
representing Chile and Venezuela.
Four isolates of Pseudomonas spp., one of P. fluorescens
(43-14926) from a blood culture isolated in December 2002 in
Santiago, Chile, and three of P. aeruginosa (49-4583, 49-4596,
and 49-4597) recovered from respiratory tract samples be-
tween August and September 2002 from the same hospital in
Caracas, Venezuela, were obtained as part of the SENTRY
Antimicrobial Surveillance Program. According to results of
MIC tests performed as described by the National Committee
for Clinical Laboratory Standards, the isolates were resistant to
all -lactams, aminoglycosides, quinolones, and other antimi-
crobial agents tested (Table 1). Only polymyxin B was active
against all the isolates. MBL phenotypic tests were positive as
judged by the disk approximation method (imipenem, mero-
penem, ceftazidime, EDTA, and 2-mercaptopropionic acid)
and the Etest MBL strips (AB Biodisk, Solna, Sweden) (7).
These results were confirmed by spectrophotometric assays
measuring imipenem hydrolysis, as previously described (4).
Imipenem hydrolysis was inhibited by 88 to 97% for each of the
strains by EDTA (20 mM) (Table 2).
Amplification with primers for the internal region of blaVIM-
like genes and 5 conserved sequence and 3 conserved se-
quence from class 1 integron and subsequent sequencing were
performed as described earlier (3, 5). Primers used for ampli-
fication and sequencing of the blaVIM gene were VIM-F (5-
AAAGTTATGCCGCACTCACC-3) and VIM-R (5-TGCA
ACTTCATGTTATGCCG-3).
Sequencing results of the PCR amplicons revealed the pres-
ence of the blaVIM-2 gene in the first position of a class 1
integron, which has qacE/su1l downstream of the MBL gene.
This integron gene arrangement has been previously reported
for a P. aeruginosa isolate from a patient in France in 1996 (3).
Other cases have been reported from P. aeruginosa in Greece
in 2000 and from Serratia marcescens in Korea in 2002 (6, 8).
Class 1 integrons carrying blaVIM-type genes are now reported
to contain genes encoding aminoglycoside-modifying enzymes,
and it is uncertain whether the arrangement of the integron
without the additional genes is the progenitor.
Despite repeated attempts, plasmid DNA analysis of the
isolates did not show any plasmids, and transformation exper-
iments were unsuccessful. Experiments in conjugation between
the clinical isolates and Escherichia coli K-12 Rifr did not yield
any transconjugants. These data imply that the blaVIM-2 found
in these isolates is likely to be chromosomally carried. Auto-
TABLE 1. Antimicrobial susceptibility profiles of the blaVIM-2-
carrying Pseudomonas sp. isolates
Antimicrobial agent
MIC (g/ml)
P. fluorescens
43-14926
P. aeruginosa
49-4583 49-4596 49-4597
-Lactams
Cefazolin 16 16 16 16
Cefoxitin 32 32 32 32
Aztreonam 16 16 16 16
Cefuroxime 16 16 16 16
Ceftriaxone 32 32 32 32
Ceftazidime 16 16 16 16
Cefepime 16 16 16 16
Imipenem 8 8 8 8
Meropenem 8 8 8 8
Piperacillin-tazobactam 64 64 64 64
Quinolones
Ciprofloxacin 4 4 4 4
Gatifloxacin 4 4 4 4
Levofloxacin 4 4 4 4
Aminoglycosides
Amikacin 8 32 32 32
Gentamicin 8 8 8 8
Netilmicin 32 32 32 32
Tobramycin 16 16 16 16
Others
Polymyxin B 1 1 1 1
Tetracycline 8 8 8 8
Trimethoprim-
sulfamethoxazole
2 2 2 2
TABLE 2. MICs by Etest MBL strips and imipenem hydrolytic
activities (with and without EDTA) of the blaVIM-2-carrying
Pseudomonas sp. isolates
Strain
Etest MBL MIC (g/
ml)
Hydrolytic activity
(absorbance/min) %
Inhibition
Imipenem Imipenem
 EDTA Imipenem
Imipenem
 EDTA
43-14926 256 1 0.07194 0.00384 94.6
49-4583 256 4 0.04519 0.00251 94.5
49-4596 256 6 0.10144 0.00253 97.5
49-4597 256 8 0.04359 0.00500 88.5
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mated ribotyping and pulsed-field gel electrophoresis showed
that the three isolates from Venezuela are identical, suggesting
clonal spread. The strain from Chile was unique and belonged
to a different species from those of the other MBL-producing
strains.
Dissemination of multiresistant bacteria coupled with the
plasticity of class 1 integrons suggests that resistance to main-
stay anti-Pseudomonas therapies, such as expanded-spectrum
cephalosporins and carbapenems, will continue to increase.
We urge greater local screening for MBL-producing strains
with the disk approximation tests (8; Kurokawa et al., letter)
and the Etest MBL strip (7).
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